Boston and Los Angeles – Oct 28, 2024
With Odyssey’s established track record in immunology and Terray’s cutting-edge AI and experimental capabilities, this collaboration underscores the growing role of AI in reshaping small-molecule drug development. By leveraging tNova, the partnership aims to streamline the discovery process, reduce development timelines, and improve the likelihood of success in addressing inflammatory diseases.
Strategic Collaboration to Drive Innovation in Immunology
Odyssey Therapeutics and Terray Therapeutics have entered into a strategic partnership to accelerate the discovery and development of novel small-molecule therapies targeting transcription factors. This collaboration brings together Odyssey’s expertise in immunology and transcription factor biology with Terray’s AI-driven tNova platform, which integrates large-scale proprietary experimental data to enhance drug discovery.
Harnessing AI to Unlock Transcription Factor Targets
By combining Odyssey’s deep knowledge of disease pathology with tNova’s computational power, the companies aim to develop first-in-class therapeutic candidates for inflammatory diseases. Transcription factors have long been considered challenging drug targets, but this collaboration seeks to overcome these hurdles through AI-driven discovery and advanced molecular design.
Joint R&D with Shared Risk and Reward
Under the agreement, both companies will contribute expertise and resources to identify and develop promising drug candidates. Odyssey will provide its proprietary insights in protein and structural biology, while Terray will leverage tNova for hit identification and lead optimization. Responsibilities for research, development, and commercialization will be shared, with both partners equally dividing potential profits and losses.
Leadership Perspectives on the Collaboration
Dr. Gary D. Glick, Founder and CEO of Odyssey, emphasized the transformative potential of the partnership, stating:
“Terray’s AI-driven discovery platform is a powerful complement to our expertise in immunology and transcription factor drug discovery. Together, we have the opportunity to develop groundbreaking therapies that address significant unmet needs in inflammatory diseases.”
Dr. Jacob Berlin, CEO of Terray Therapeutics, echoed this sentiment, highlighting the synergy between the two companies:
“Our generative AI capabilities, powered by ultra-miniaturized chemistry, align perfectly with Odyssey’s expertise in transcription factor biology. This collaboration represents a major step toward solving complex drug discovery challenges and delivering meaningful solutions for patients.”
About Terray Therapeutics
Terray Therapeutics is a biotechnology company pioneering a data-driven approach to small-molecule drug discovery. By integrating ultra-high throughput experimentation, generative AI, medicinal chemistry, and nanotechnology, Terray’s platform enables rapid and efficient identification of promising drug candidates. The company’s tNova platform blends large-scale proprietary experimental data with AI-driven insights to advance the next generation of precision therapeutics.
More about news
About Odyssey Therapeutics
Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the standard of care for patients with autoimmune and inflammatory diseases. Founded in 2021, Odyssey brings together world-class drug discovery expertise and a comprehensive suite of tools to develop targeted therapies aimed at inducing deep and durable remission. The company’s internally discovered product candidates are designed to precisely address disease pathology, offering new hope for patients with significant unmet medical needs.
By